Related Experiment Video
Updated: Jun 18, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Dendritic cell vaccines for brain tumors
1UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS 74-145, Los Angeles, CA 90095-6901, USA.
Abstract:
Over the past decade, dendritic cell-based immunotherapy for central nervous system tumors has progressed from preclinical rodent models and safety assessments to phase I/II clinical trials in over 200 patients, which have produced measurable immunologic responses and some prolonged survival rates. Many questions regarding the methods and molecular mechanisms behind this new treatment option, however, remain unanswered. Results from currently ongoing and future studies will help to elucidate which dendritic cell preparations, treatment protocols, and adjuvant therapeutic regimens will optimize the efficacy of dendritic cell vaccination. As clinical studies continue to report results on dendritic cell-mediated immunotherapy, it will be critical to continue refining treatment methods and developing new ways to augment this promising form of glioma treatment.
Insights
Dendritic cell immunotherapy for brain tumors shows promise, with clinical trials demonstrating immune responses and improved survival. Further research is needed to optimize treatment methods and enhance efficacy for glioma patients.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular therapy
Background:
- Dendritic cell (DC)-based immunotherapy has emerged as a novel treatment strategy for central nervous system (CNS) tumors.
- Over the last decade, this approach has advanced from preclinical studies to Phase I/II clinical trials.
Purpose of the Study:
- To review the progress of DC-based immunotherapy for CNS tumors.
- To identify unanswered questions regarding methods and molecular mechanisms.
- To highlight the need for optimizing DC vaccination protocols and adjuvant therapies for improved glioma treatment.
Main Methods:
- Review of preclinical rodent models and safety assessments.
- Analysis of data from over 200 patients in Phase I/II clinical trials.
- Evaluation of immunologic responses and survival rates.
Main Results:
- DC-based immunotherapy has yielded measurable immunologic responses in patients with CNS tumors.
- Some studies have reported prolonged survival rates.
- The field still requires answers regarding optimal DC preparations, treatment protocols, and adjuvant regimens.
Conclusions:
- DC-based immunotherapy is a promising treatment for gliomas.
- Ongoing and future studies are crucial for refining treatment strategies and augmenting efficacy.
- Continued research is essential to optimize DC vaccination for better patient outcomes.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy